Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

192 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effectiveness of two strategies to follow-up ASC-US and LSIL screening results in The Netherlands using repeat cytology with or without additional hrHPV testing: a retrospective cohort study.
Siebers AG, Arbyn M, Melchers WJ, van Kemenade FJ, Vedder JE, van der Linden H, van Ballegooijen M, Bekkers RL, Bulten J. Siebers AG, et al. Among authors: van der linden h, van kemenade fj, van ballegooijen m. Cancer Causes Control. 2014 Sep;25(9):1141-9. doi: 10.1007/s10552-014-0414-2. Epub 2014 Jun 17. Cancer Causes Control. 2014. PMID: 24935226
Liquid-based cervical cytology using ThinPrep technology: weighing the pros and cons in a cost-effectiveness analysis.
de Bekker-Grob EW, de Kok IM, Bulten J, van Rosmalen J, Vedder JE, Arbyn M, Klinkhamer PJ, Siebers AG, van Ballegooijen M. de Bekker-Grob EW, et al. Among authors: van rosmalen j, van ballegooijen m. Cancer Causes Control. 2012 Aug;23(8):1323-31. doi: 10.1007/s10552-012-0011-1. Epub 2012 Jun 17. Cancer Causes Control. 2012. PMID: 22706692 Clinical Trial.
Comparing SurePath, ThinPrep, and conventional cytology as primary test method: SurePath is associated with increased CIN II+ detection rates.
Rozemeijer K, Penning C, Siebers AG, Naber SK, Matthijsse SM, van Ballegooijen M, van Kemenade FJ, de Kok IM. Rozemeijer K, et al. Among authors: van kemenade fj, van ballegooijen m. Cancer Causes Control. 2016 Jan;27(1):15-25. doi: 10.1007/s10552-015-0678-1. Epub 2015 Oct 12. Cancer Causes Control. 2016. PMID: 26458884 Free PMC article.
Human papillomavirus testing on self-sampled cervicovaginal brushes: an effective alternative to protect nonresponders in cervical screening programs.
Bais AG, van Kemenade FJ, Berkhof J, Verheijen RH, Snijders PJ, Voorhorst F, Babović M, van Ballegooijen M, Helmerhorst TJ, Meijer CJ. Bais AG, et al. Among authors: van kemenade fj, van ballegooijen m. Int J Cancer. 2007 Apr 1;120(7):1505-10. doi: 10.1002/ijc.22484. Int J Cancer. 2007. PMID: 17205514 Free article. Clinical Trial.
Trends in cervical cancer in the Netherlands until 2007: has the bottom been reached?
de Kok IM, van der Aa MA, van Ballegooijen M, Siesling S, Karim-Kos HE, van Kemenade FJ, Coebergh JW; Working Group Output of the Netherlands Cancer Registry. de Kok IM, et al. Among authors: van der aa ma, van kemenade fj, van ballegooijen m. Int J Cancer. 2011 May 1;128(9):2174-81. doi: 10.1002/ijc.25553. Int J Cancer. 2011. PMID: 20626043 Free article.
POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women.
Bulkmans NW, Rozendaal L, Snijders PJ, Voorhorst FJ, Boeke AJ, Zandwijken GR, van Kemenade FJ, Verheijen RH, v Groningen K, Boon ME, Keuning HJ, van Ballegooijen M, van den Brule AJ, Meijer CJ. Bulkmans NW, et al. Among authors: van den brule aj, van kemenade fj, van ballegooijen m. Int J Cancer. 2004 May 20;110(1):94-101. doi: 10.1002/ijc.20076. Int J Cancer. 2004. PMID: 15054873 Free article. Clinical Trial.
Offering Self-Sampling to Non-Attendees of Organized Primary HPV Screening: When Do Harms Outweigh the Benefits?
Rozemeijer K, de Kok IM, Naber SK, van Kemenade FJ, Penning C, van Rosmalen J, van Ballegooijen M. Rozemeijer K, et al. Among authors: van rosmalen j, van kemenade fj, van ballegooijen m. Cancer Epidemiol Biomarkers Prev. 2015 May;24(5):773-82. doi: 10.1158/1055-9965.EPI-14-0998. Epub 2014 Nov 28. Cancer Epidemiol Biomarkers Prev. 2015. PMID: 25432954
192 results